BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 4 February 1997.
Eric Krasnoff, Chairman and CEO of Pall Corporation, stated, "We are excited to work with LifeTECH to dramatically improve the safety and purity of the world's blood supply. Pathogen inactivation addresses the very serious problem of virus and bacterial contamination of blood products, including the HIV virus. Once approved, we expect this technology to be rapidly adopted."
Walter J. Dermott, President and Chief Executive Officer of LifeTECH, stated, "This strategic alliance with Pall Corporation is an important step forward for our technology and our goal of making the global blood supply safe. This added value will make Pall's blood collection sets unique in the global marketplace, and will make LifeTECH's technology the industry leader in the fight against viruses and bacteria in the blood supply."
Pall Corporation, with annual sales over $1 billion, is headquartered in East Hills, New York. The Company has the broadest based filtration and separations capabilities in the world. Since 1946, Pall Corporation has demonstrated technological leadership and innovative solutions to complex fluid clarification and purification problems in each of its three major markets, Health Care, Aeropower and Fluid Processing. The Company employs nearly 9,000 people in facilities throughout the world. The Company's shares are listed on the New York Stock Exchange (PLL) and the London Stock Exchange (0668260).
LifeTECH Corporation is a Canadian biotechnology company dedicated to developing and commercializing innovative technologies to sterilize blood and other biological fluids. LifeTECH's Sterinetics(TM) System is designed to inactivate viruses and bacteria in the global blood supply, including the HIV and Hepatitis viruses. LifeTECH common shares (LFTK) and warrants (LFTK.WT) trade on the Canadian Dealing Network.
--30--sdg/ny*
CONTACT: Pall Corporation Patricia Iannucci (516) 484-3600
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
970204
BW970202
ÆGIS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGiS, or the party credited as the provider of the content.